Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation-Reference-Cited by-同舟云学术

Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation

Published:2023-11-01 Issue: Volume: Page:
ISSN:1672-9145
Container-title:Acta Biochimica et Biophysica Sinica
language:en
Short-container-title:ABBS

Author:

Jin Shuhan,Li Bo,Zhang Bibo,Gao Xuejie,Jia Xinyan,Xu Li,Chang Shuaikang,Hu Ke,Wang Guanli,Xu Zhijian,Zhang Ting,Song Dongliang,Yang Guang,Wu Xiaosong,Zhu Huabin,Huang Cheng,Lu Yumeng,Shi Jumei,Zhu Weiliang,Chen Gege

Publisher

China Science Publishing & Media Ltd.

Subject

General Medicine,Biochemistry,Biophysics,Molecular Biology

Link

https://engine.scichina.com/doi/pdf/6371163710274B1AA9A5A8F17D39D243

Reference31 articles.

1. Firth J. Haematology: multiple myeloma. Clini Med (London, England) 2019, 19: 58–60.

2. Twombly R. First proteasome inhibitor approved for multiple myeloma. J Natl Cancer Inst 2003, 95: 845–845.

3. Dimopoulos MA, Richardson PG, Moreau P, Anderson KC. Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol, 2015, 12: 42-54.

4. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management. Am J Hematol, 2020, 95: 548-567.

5. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med, 2006, 57: 33-47.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The ERK1/2-Elk1, JNK-cJun, and JAK-STAT Transcriptional Axes as Potential Bortezomib Resistance Mediators in Prostate Cancer;2024-04-20

2. Dihydrocelastrol induces cell death and suppresses angiogenesis through BCR/AP-1/junb signalling in diffuse large B cell lymphoma;Archives of Biochemistry and Biophysics;2024-04